SCHEMBL7609540

SCHEMBL7609540

Cc1nnc(SC(CCCCSc2nsnc2C2=CCCN(C)C2)OC(=O)C(=O)OC(CCCCSc2nsnc2C2=CCCN(C)C2)Sc2nnc(C)s2)s1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 10/20 0.60
CHRM4 P08173 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7617514 0.99 CHRM1 (0.60) CHRM1CHRM4
SCHEMBL7617535 0.98 CHRM1 (0.58) CHRM1CHRM4
Oxalic Acid SCHEMBL7617531 0.85 CHRM1 (0.69) CHRM1CHRM4
SCHEMBL7618497 0.84 CHRM1 (0.77) CHRM1CHRM4
Oxalic Acid SCHEMBL7617509 0.84 CHRM1 (0.69) CHRM1CHRM4
Oxalic Acid SCHEMBL7609535 0.84 CHRM1 (0.69) CHRM1CHRM4
SCHEMBL7610832 0.84 CHRM1 (0.60) CHRM1CHRM4
SCHEMBL7617184 0.84 CHRM1 (0.55) CHRM1CHRM4
SCHEMBL7612166 0.83 CHRM1 (0.78) CHRM1CHRM4
SCHEMBL7614713 0.83 CHRM1 (0.78) CHRM1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734259-B1 Use of piperidine compounds in the treatment of schizophrenia NOVO NORDISK AS (DK) 2002-06-12 EP disclosed
US-RE36375-E Treatment of Alzheimer's disease using azacyclic compounds NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
US-5919805-A 3-OXY- OR THIO-DERIVATIVES OF 1,2,5-OXADIAZOLES OR 1,2,5-THIADIAZOLES; TREATMENT OF ALZHEIMER'S DISEASE, SEVERE PAINFUL CONDITIONS AND GLAUCOMA. NOVO NORDISK A/S (DK) 1999-07-06 US disclosed
US-5773452-A ALZHEIMER'S DISEASE; COGNITION ACTIVATORS NOVO NORDISK ALS (DK) 1998-06-30 US disclosed
US-RE35822-E COGNITION ACTIVATORS NOVO NORDISK A/S (DK) 1998-06-09 US disclosed
US-5753683-A SCHIZOPHRENIA NOVO NORDISK A/S (DK) 1998-05-19 US disclosed
US-5750541-A 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION NOVO NORDISK A/S (DK) 1998-05-12 US disclosed
US-5744489-A ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS GREENWOOD BEVERLEY (US) 1998-04-28 US disclosed
US-5658932-A AZACYCLIC COMPOUNDS; COGNITIVE FUNCTION STIMULANTS; ALZHEIMER'S DISEASE NOVO NORDISK A/S (DK) 1997-08-19 US disclosed
US-5565475-A Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives MUHLHAUSER MARK A (US) 1996-10-15 US disclosed
EP-0734259-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1996-10-02 EP disclosed
US-5559136-A Treatment of Alzheimer's disease using azacyclic compounds NOVO NORDISK A/S (DK) 1996-09-24 US disclosed
EP-0687265-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-12-20 EP disclosed
WO-1995005174-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO disclosed
US-5376668-A Cholinergic agents as cognition activators in treatment of Alzheimer*s disease NOVO NORDISK A/S (DK) 1994-12-27 US disclosed
WO-1994020495-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO disclosed